9,000
Participants
Start Date
January 6, 2014
Primary Completion Date
December 31, 2028
Study Completion Date
June 30, 2029
Secretin
inject Secretin to stimulate pancreatic digestive fluid, which is collected in duodenum near ampulla via endoscope suction port. This fluid will be assessed for biomarkers.
MRI
MRI abdomen with contrast (MRCP) will be clinically indicated for abnormal novel CA-19-9 lab results.
Tumor marker gene test with CA19-9
A tumor marker gene test that will be used to stratify individuals into one of several circulating tumor marker reference ranges for CA19-9. The variants in the genes FUT3 and FUT2 affect the levels of CA19-9.
RECRUITING
NYU Langone Medical Center, New York
RECRUITING
Columbia University Medical Center, New York
RECRUITING
University of Pittsburgh, Pittsburgh
RECRUITING
University of Pennsylvania, Philadelphia
RECRUITING
Johns Hopkins Hospital, Baltimore
RECRUITING
Case Comprehensive Cancer Center, Case Western Medical Reserve, Cleveland
RECRUITING
University of Michigan, Ann Arbor
RECRUITING
Yale University, New Haven
RECRUITING
Dana Farber Cancer Center, Harvard University, Boston
National Cancer Institute (NCI)
NIH
National Institutes of Health (NIH)
NIH
American Association for Cancer Research
OTHER
Johns Hopkins University
OTHER